Zafgen, Inc. (ZFGN) Upgraded by Zacks Investment Research to Buy

Zacks Investment Research upgraded shares of Zafgen, Inc. (NASDAQ:ZFGN) from a hold rating to a buy rating in a report released on Saturday, July 8th. They currently have $4.00 price objective on the biopharmaceutical company’s stock.

According to Zacks, “Zafgen, Inc. is a biopharmaceutical company. The Company develops therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection that is in Phase II clinical trials for the treatment of various indications comprising obesity and hyperphagia in Prader-Willi Syndrome patients, craniopharyngioma-associated obesity, and severe obesity in the general population. Zafgen, Inc. is headquartered in Cambridge, Massachusetts. “

A number of other equities research analysts have also issued reports on ZFGN. ValuEngine raised shares of Zafgen from a strong sell rating to a sell rating in a report on Thursday, July 6th. Cowen and Company reissued a hold rating on shares of Zafgen in a report on Friday, March 10th. Finally, Roth Capital started coverage on shares of Zafgen in a research note on Thursday, April 20th. They set a buy rating and a $9.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the stock. Zafgen presently has a consensus rating of Hold and a consensus price target of $14.67.

Zafgen (ZFGN) opened at 3.67 on Friday. The company’s 50 day moving average price is $3.80 and its 200 day moving average price is $4.11. The firm’s market cap is $100.46 million. Zafgen has a 52-week low of $2.89 and a 52-week high of $6.87.

Zafgen (NASDAQ:ZFGN) last issued its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by $0.05. Analysts predict that Zafgen will post ($2.34) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Zafgen, Inc. (ZFGN) Upgraded by Zacks Investment Research to Buy” was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://sportsperspectives.com/2017/07/18/zafgen-inc-zfgn-rating-increased-to-buy-at-zacks-investment-research-updated.html.

In other Zafgen news, insider Dennis D. Kim purchased 10,000 shares of the stock in a transaction that occurred on Thursday, May 11th. The stock was bought at an average cost of $4.40 per share, with a total value of $44,000.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 21.20% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Dimensional Fund Advisors LP boosted its position in shares of Zafgen by 41.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 306,462 shares of the biopharmaceutical company’s stock worth $975,000 after buying an additional 89,805 shares during the period. Federated Investors Inc. PA boosted its position in shares of Zafgen by 27.0% in the fourth quarter. Federated Investors Inc. PA now owns 129,661 shares of the biopharmaceutical company’s stock valued at $412,000 after buying an additional 27,533 shares during the period. Candriam Luxembourg S.C.A. boosted its position in shares of Zafgen by 97.2% in the first quarter. Candriam Luxembourg S.C.A. now owns 213,000 shares of the biopharmaceutical company’s stock valued at $993,000 after buying an additional 105,000 shares during the period. Nine Chapters Capital Management LLC purchased a new position in shares of Zafgen during the first quarter valued at about $170,000. Finally, JPMorgan Chase & Co. boosted its position in shares of Zafgen by 937.6% in the first quarter. JPMorgan Chase & Co. now owns 495,743 shares of the biopharmaceutical company’s stock valued at $2,311,000 after buying an additional 447,964 shares during the period. 52.00% of the stock is owned by institutional investors.

About Zafgen

Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.

Get a free copy of the Zacks research report on Zafgen (ZFGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply